Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer. by Matsui, K. et al.
British Joumal ofCancer (1998) 77(11), 1961-1965
© 1998 Cancer Research Campaign
Phase 11 trial of carboplatin plus oral etoposide for
elderly patients with small-cell lung cancer
K Matsui1, N Masuda1, M Fukuoka2, T Yana1, T Hirashima1, T Komiya1, M Kobayashi1, M Kawahara3, S Atagi3,
M Ogawara3, S Negoro2, S Kudoh4 and K Furuse3
'Second Department of Internal Medicine, Osaka Prefectural Habikino Hospital, 3-7-1 Habikino, Habikino Osaka 583, Japan; 2Department of Respiratory
Disease, Osaka City General Hospital, 53, Miyakojima-hondori 2-chome, Miyakojima-ku, Osaka 534, Japan; 3Department of Internal Medicine, National Kinki
Central Hospital, 1180 Nagasone, Sakai Osaka 591, Japan; 4First Department of Internal Medicine, Osaka City University School of Medicine, 1-5-7, Asahi-
machi, Abenoku, Osaka 545, Japan
Summary A phase 11 trial was conducted to evaluate the efficacy and toxicity of the Egorin's carboplatin dosing formula with 14-day oral
etoposide in 38 elderly patients with small-cell lung cancer (SCLC). The overall response rate was 81%. Median survival times were 15.1
months for 16 limited-disease (LD) and 8.6 months for 22 extensive-disease (ED) patients. Myelosuppression was the principal side-effect.
This regimen is an active regimen in the treatment of elderly SCLC patients.
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The incidence of small-cell lung cancer (SCLC) increases expo-
nentially with age. Almost 25% of the patients with this disease
are aged older than 70 years (Carney et al, 1990). Over the past
decades, cytotoxic therapy has been the mainstay of treatment for
SCLC. However, many elderly patients receive less chemotherapy,
with more dose reductions and fewer cycles, because they may
have a lesser ability to tolerate these therapies (Dajczman et al,
1996). An age-related decrease in physiological functions is well
known, and a wide interpatient variability of physiological func-
tions and organ reserves exists in older patients. Therefore, cancer
chemotherapy in the elderly may be the best example of the need
for dose optimization for individual patients.
Carboplatin is an active cisplatin analogue (Smith et al, 1985).
The dose-limiting toxicity is myelosuppression, with thrombo-
cytopenia being more marked than leucopenia. Carboplatin is
unique in that the systemic drug exposure in a patient can be
predicted on the basis of that patient's renal function (Egorin et al,
1984; Calvert et al, 1989).
Etoposide has currently become a standard part of most regi-
mens for the treatment of patients with SCLC. It can also yield
excellent results even when used as a single agent in elderly
patients (Smit et al, 1989; Clark et al, 1990; Johnson et al,
1990). As etoposide shows marked schedule dependency
(Dombernowsky and Nissen, 1973), a prolonged schedule of
etoposide administration may be superior to the 3-day or 5-day
schedule (Cavalli et al, 1978; Slevin et al, 1989). The combination
of carboplatin and etoposide has been proven to be synergistic
against animal tumour models (Schabel et al, 1979). As tolerance
to myelosuppressive agents might be decreased in elderly patients,
a conservative dose of 40 mg m-2 day-' of etoposide for 14 days,
Received 9April 1997
Revised23 October 1997
Accepted 30 October 1997
Correspondence to: N Masuda, Department of Internal Medicine, Osaka
Prefectural Habikino Hospital, 3-7-1 Habikino, Habikino Osaka 583, Japan
corresponding to 53% of the maximum tolerated dose (MTD) as a
single agent (Hainsworth et al, 1989), was carefully selected in
this combination regimen.
The objectives of our study were to determine the applicability
of the Egorin et al (1984) carboplatin dosing formula with oral
etoposide, and to evaluate the efficacy of this combination
regimen in elderly SCLC patients.
MATERIALS AND METHODS
Patient eligibility
Patient selection was restricted to those over 70 years of age with
no prior therapy and with histologically or cytologically proven
SCLC. Eligibility stipulated measurable disease, ECOG perfor-
mance status of 0-3, adequate hepatic function, adequate renal
function with normal serum creatinine and creatinine clearance
> 30 ml min-', adequate bone marrow reserve, adequate cardiac
functions, no active concomitant malignant disease and the written
informed consent ofthe patient.
Evaluation
Pretreatment evaluation consisted of complete medical history,
physical examination, urinalysis and full blood chemistry. Staging
procedures included chest radiograph, bone scintiscan, bone
marrow aspiration, computerized tomography of the head, chest
and abdomen, and fibre optic bronchoscopy. The assessments of
full blood chemistry were repeated at least once a week after the
initial assessment. After the completion of chemotherapy, each
patient was restaged by performing all the tests used during the
initial work-up. The eligibility, evaluability and response of each
patient were assessed by extramural reviewers.
Dose calculation and administration
Etoposide (40 mg m-2) was given on days 1 through 14. During the
14-day course of etoposide, it was discontinued until recovery if
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Table 1 Patient characteristics
Characteristic Number of cases
No. of patients 38
Median age in years (range) 78 (73-84)
Sex (male/female) 30/8
Performance status (ECOG)
0,1 25
2 11
3 2
Stage
Limited disease 16
Extensive disease 22
Sites of metastases
Lung 6
Brain 5
Bone 4
Liver 3
Lymph node 2
Contralateral pleural effusion 2
Bone marrow 1
Subcutaneous nodule 1
Pancreas 1
Twenty-four-hour creatinine clearance
>60 ml min-' 16
< 60 ml min-' 22
Table 2 Therapeutic response
No. of assessable CR PR NC PD Overall
patients response
LD 15 2 12 1 0 14 (93)
ED 21 0 15 3 3a 15 (71)
Total 36 2 27 4 3a 29 (81)
aTwo treatment-related deaths were observed in ED patients. Numbers in
parentheses are percentages. CR, complete response; PR, partial response;
NC, no change; PD, progressive disease.
Table 3 Haematological toxicity
Toxicity No. of Grade No. of patients
patients > grade 3
1 2 3 4
Leucopenia 36 6 11 13 5 18 (50)
Neutropenia 36 7 9 12 7 19 (53)
Thrombocytopenia 36 3 6 14 5 19 (53)
Anaemia 36 7 9 15 3 18 (50)
The numbers in parentheses are percentages.
the WBC count fell below 2 x 109 1-' or if platelets fell below
50 x 109 1-'. Carboplatin was administered on day 1 intravenously
over 1 h. Carboplatin dosage was calculated for each course of
therapy for each patient using the following equation: dosage
(mg m-2) = (0.8) [(0.091) (creatinine clearance)/(body surface
area)((pretreatment platelet count-desired nadir platelet count)/
(pretreatment platelet count) x 100 - 17}+ 86]. The desired nadir
platelet count in all patients was 75 x 1091-'. To avoid excess
myelosuppression from this regimen, the dosage ofcarboplatin was
reduced by 20% from the originally calculated dosage for previ-
ously treated patients derived from Egorin et al (1984). Treatment
was repeated every 4 weeks for a total of four cycles. Patients with
progressive disease or no response after the initial two cycles were
taken off study. The carboplatin exposure in terms of area under the
concentration-time curve (AUC) was estimated retrospectively
using both the Calvert's (Calvert et al, 1989) and Chatelut's
(Chatelut et al, 1995) formulae. Chest irradiation (45 Gy) was given
for limited-disease (LD) patients after four cycles ofchemotherapy.
Response, toxicity and survival
Tumour responses and drug toxicity were classified in accordance
with the World Health Organization (WHO) criteria (World Health
Organization, 1979). The duration of survival was determined as
the number of months from the start of treatment until the date of
death or last follow-up. The method of Kaplan and Meier (1958)
was used to derive the survival curve.
RESULTS
Patients
Between March 1992 and June 1995, 38 patients were enrolled.
Two patients (one with limited disease, the other with extensive
disease) refused further therapy during their first course of treat-
ment; these patients could not be monitored adequately for
response and toxicities, but all 38 patients were assessable for
survival.
The patientcharacteristics are listed in Table 1. The median creati-
nine clearance was 56.3 ml min-', ranging from 36 to 87.5 ml min-'.
Twenty-two (58%) patients showed a creatinine clearance of
<60 mlmin-'.
Response and survival
Thirty-six patients were assessable for response. An objective
response [complete response (CR) and partial response (PR)] was
seen in 93% of patients with limited disease (LD) and in 71% for
extensive-disease (ED) patients (Table 2). The overall response
rate was 81% with a CR rate of 6%. The overall response rate of
patients over 75 years ofage was 77%. The median response dura-
tion for LD patients was 17.8 months; that for ED patients was
5.6 months.
The median survival time for all 38 patients was 10.1 months
(LD patients, 15.1 months; ED patients, 8.6 months). The 1- and 2-
year actuarial survival rates in patients with LD were 51.2% and
21.8%, compared with 34.8% and 0% in the patients with ED. The
median survival time for 33 elderly patients (. 75 years) was
9.9 months (LD patients, 10.3 months; ED patients, 7.5 months).
The projected 1- and 2-year survival rates in 13 LD patients aged
> 75 were 47.6% and 11.3%.
Toxicity
Thirty-three patients received multiple courses of treatment in
successive cycles. Table 3 shows the maximum toxicities experi-
enced during the treatment. The most frequent toxicity was myelo-
suppression. Grade 3 and 4 leucopenia occurred in 36% and 14%
of patients respectively. The median leucocyte count nadir was
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Table 4 Relation between carboplatin dose and myelosuppression
Course
1 2 3 4
No. of patients 36 33 26 19
Carboplatin dose (mg m-2) 214a 216 194 178
(164-351)a (130-392) (124-298) (96-230)
Delivered dose/planned dose of carboplatin () 1Oob 98 98 98
AUC (mg ml-1 min-1)
Calvert's formula 4.0 4.1 3.8 3.6
(2.5-6.0) (2.7-6.2) (2.3-4.5) (1.9-4.2)
Chatelut's formula 3.4 3.5 3.0 2.6
(2.3-6.8) (2.1-7.3) (2.0-5.2) (1.8-4.6)
Delivered dose/planned dose of etoposide (%) 97b 97 100 100
Creatinine clearance (ml min-1) 56.3 55 52.6 50
(36-87.5) (16.2-88) (25-87.5) (28-65.7)
Nadir leucocyte count (pl-1) 2300 2820 2450 2500
(100-5400) (1300-5100) (1100-5200) (1300-4300)
Nadir platelet count (x 103 pl-1) 65 100 92 90
(8-214) (5-250) (14-139) (12-212)
aMedian (range). bNumbers show the percentage of the drug dose actually delivered vs the planned dose during each course.
2.5 x 109 1-' with a range of 0.1-5.4 x 109 1-. The leucocyte nadir
usually occurred around day 20, with recovery in most patients by
day 28. Granulocyte colony-stimulating factor was given in 28
courses to 17 patients. There were three neutropenic febrile
episodes. Grade 3 and 4 thrombocytopenia occurred in 39% and
14% of the patients respectively (Table 3). The median platelet
nadir was 88 x 109 1-', with a range of5-250 x 109 1-'. Seven ofthe
114 courses produced platelet nadirs of < 25 x 109 1-1. Eight
patients required platelet transfusions, but there were no bleeding
episodes during chemotherapy-induced thrombocytopenia. Fifty
per cent ofpatients had grade 3 or 4 anaemia (Table 3). Red blood
cell transfusions were performed for ten courses for eight patients.
Non-haematological toxicities were infrequent. Gastrointestinal
toxicity was the prominent toxic effect of this treatment. Grade 3
nausea and vomiting occurred in three patients. No severe toxici-
ties were observed in the urinary bladder, kidney or liver.
There were two induction deaths in patients with massive
pleural effusion.
Drug delivery
Although the percentages of the drug dose actually delivered vs
the planned dose during each course were quite well preserved for
both drugs (98-100% for carboplatin, 97-100% for etoposide),
only 19 (50%) of38 patients were able to complete all four courses
(Table 4). Dose reduction for carboplatin was carried out in six
courses. Dose omission for etoposide was performed in two
courses. There was no correlation between the age and the carbo-
platin dose actually administered in a total of 114 courses (r =
- 0.0254, P = 0.7807). The estimated AUCs based on Calvert's
formula (median 3.9 mg ml-' min, range 1.9-6.2 mg ml-' min)
were higher than those calculated using Chatelut's formula
(median 3.2 mg ml- min, range 1.8-7.3 mg ml' min). There was
no apparent deterioration of renal function with this treatment
during the trial.
DISCUSSION
The overall response rate of 88% and the median survival time of
10.1 months (LD patients, 15.1 months; ED patients, 8.6 months)
obtained in our phase II trial of carboplatin and oral etoposide
compare favourably with other results reported for younger
patients aged under 75 years (Aisner et al, 1983; Fukuoka et al,
1991). The use of carboplatin and etoposide has been reported in
several studies (Bishop et al, 1987; Smith et al, 1987; Evans et al,
1988, 1995; Wolf et al, 1991; Luikart et al, 1993; Camey, 1995;
Pfeiffer et al, 1995). As there is a wide range in the pretreatment
renal functions of elderly patients (Table 4), which profoundly
affects the severity ofcarboplatin-induced thrombocytopenia, dose
calculations based on renal function seem to be preferable to those
simply based on the body surface area of the patients alone.
However, individualized dosing of carboplatin in the treatment of
SCLC has not been reported in other published studies. In this
trial, the dosing of carboplatin was individualized using the
formula derived by Egorin et al (1985). The majority of patients
enrolled into the study tolerated treatment well and could receive
the planned dose of carboplatin during four cycles (98-100%)
(Table 4). Although grade 4 thrombocytopenia was observed in
14% of 36 patients (Table 3), only 6% of treatment cycles were
complicated by fourth-degree thrombocytopenia.
With respect to the schedule ofetoposide administration, etopo-
side was usually given intravenously for 3 consecutive days in
most of the trials. Miller et al (1995) compared 3-day infusion of
etoposide plus cisplatin with 21-day oral etoposide plus cisplatin.
In their study, although the two schedules of etoposide did not
make any difference in the treatment outcome, a significantly
higher rate of severe or life-threatening myelotoxicity was
observed in the 21-day oral etoposide treatment group. Use of 21-
day oral etoposide in combination seems to be too toxic and inap-
propriate for elderly patients. Oral etoposide 50 mg twice daily for
10 days (Medical Research Council Lung Cancer Working Party,
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1996) and 100 mg given twice daily for 5 days (Souhami et al,
1997) were inferior in terms of survival to standard intravenous
chemotherapy. Evans et al (1995) reported that 66% of patients
who were treated with carboplatin and oral etoposide 100 mg m-)
for 7 days had grade 4 neutropenia. Their median age of 69 years
was 9 years younger than in our study (78 years), and there was a
higher frequency of septic deaths (8.5%) in their study than in the
present study (5.3%). According to the retrospective analysis of
Siu et al (1996), 64% of LD patients over 70 years of age who
were treated with etoposide and cisplatin alternating with
cyclophosphamide+doxorubicin+vincristine developed grade 4
neutropenia. In this study only 19% of patients experienced grade
4 neutropenia (Table 3). Therefore, a combination of carboplatin
and etoposide with oral administration of 40 mg m-2 of etoposide
per day for 14 days may be more tolerable and suitable for the
elderly. However, we experienced two treatment-related deaths in
patients with massive pleural effusion. As pleural effusion may act
as a third space on the metabolism of anti-cancer agents, the
retention of anti-cancer agents can occur in massive effusions.
Therefore, it seems better to minimize the risk of unexpected
severe toxicity by aspirating massive effusion before the start of
chemotherapy.
Siu et al (1996) reported the effect of age on the treatment
outcome of LD-SCLC. Sixty-nine per cent ofpatients older than 70
years were capable ofreceiving full treatment cycles. However, only
6 (46%) of 13 patients aged over 75 years were able to complete all
six treatment cycles, and their overall response rate of 64% was
lower than the response rate of 78% and 85% for the 0-69 and
70-75 years age groups. The over 75 years age group showed the
poorest survival time, and all died within 2 years after diagnosis
despite the fact that patients greater than 80 years of age were
excluded from the trials. In contrast, 33 LD patients over 75 years of
age showed a high response rate of 77% and the median survival
time of 10.3 months, with a 2-year survival rate of 11.3% in ourtrial.
In conclusion, carboplatin dosing based on the Egorin's
formula, rather than simply on a mg m-2 basis, in combination with
oral etoposide seems to be active and to minimize the likelihood of
unacceptable and unexpected myelotoxicity in elderly patients
with SCLC, except for patients with massive pleural effusion.
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